Table 2.

Supporting International Pediatric NHL Response Criteria Data

Supporting Information	Description
BM involvement	Currently defined by morphologic evidence of lymphoma cells; this applies to any histologic subtype; type and degree of BM involvement should be specified*
BMm	BM positive by morphology (specify percentage of lymphoma cells)
BMi	BM positive by immunophenotypic methods (histochemical or flow cytometric analysis; specify percentage of lymphoma cells)
BMc	BM positive by cytogenetic or FISH analysis (specify percentage of lymphoma cells)
BMmol	BM positive by molecular techniques
CNS involvement
CSF status	CSF positivity is based on morphologic evidence of lymphoma cells; CSF should be considered positive when any number of blasts is detected; CSF may be unknown; as with BM, type of CSF involvement should be described whenever possible
CSFm	CSF positive by morphology (specify No. of blasts/μL)
CSFi	CSF positive by immunophenotype methods (histochemical or flow cytometric analysis; specify percentage of lymphoma cells)
CSFc	CSF positive by cytogenetic or FISH analysis (specify percentage of lymphoma cells)
CSFmol	CSF positive by molecular techniques
RM
RMm	Tumor detected by standard morphologic evaluation
RMi	Tumor detected by immunophenotypic methods (immunohistochemical or flow cytometric analysis)
RMc	Tumor detected by cytogenetic or FISH analysis
RMmol	Tumor detected by molecular techniques

Abbreviations: BM, bone marrow; FISH, fluorescent in situ hybridization; NHL, non-Hodgkin lymphoma; PB, peripheral blood; RM, residual mass.

^*Same approach should be used for PB involvement (ie, PBm, PBi, PBc, PBmol).